Clincosm LogoSign in Get a demo

Expanded Access to Elezanumab

Sponsor
AbbVie (Industry)
Overall Status
Available
CT.gov ID
NCT04278235
Collaborator
(none)

Study Details

Study Description

Brief Summary

This is an expanded access program (EAP) for eligible participants. This program is designed to provide access to Elezanumab prior to approval by the local regulatory agency. Availability will depend on territory eligibility. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.

Condition or Disease Intervention/Treatment Phase

Study Design

Study Type:
Expanded Access
Official Title:
Expanded Access to Elezanumab

Outcome Measures

Primary Outcome Measures

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years and Older
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    • The participant must not be eligible for an elezanumab clinical trial.

    Contacts and Locations

    Locations

    No locations specified.

    Sponsors and Collaborators

    • AbbVie

    Investigators

    • Study Director: ABBVIE INC., AbbVie

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    AbbVie
    ClinicalTrials.gov Identifier:
    NCT04278235
    Other Study ID Numbers:
    • C20-203
    • C20-284
    • C20-285
    First Posted:
    Feb 20, 2020
    Last Update Posted:
    Mar 24, 2022
    Last Verified:
    Mar 1, 2022
    Keywords provided by AbbVie
    Expanded Access
    Pre-approval Access
    Compassionate Use
    Special Access Program
    Named Patient Basis
    Special Access Scheme
    Additional relevant MeSH terms:
    Spinal Cord Injuries
    Ischemic Stroke

    Study Results

    No Results Posted as of Mar 24, 2022